• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    NovaBay Pharmaceuticals Reports Record Amazon Prime Day Sales

    7/30/24 6:50:00 AM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NBY alert in real time by email

    NovaBay Pharmaceuticals, Inc. (NYSE:NBY) reports record sales of Avenova®-branded eyecare products during the Amazon Prime Day event, which was held July 16-17, 2024. Over the two-day period, Avenova sales were 17% higher compared with Prime Day 2023 and were up 40% over Prime Day 2022.

    "We reached another new sales record during the 2024 Amazon Prime Day event as consumers took advantage of discounts on our high-quality Avenova products," said Justin Hall, NovaBay CEO. "This event offered great pricing to our repeat customers on the Avenova products they've come to rely on, as well as to those new to our brand and our best-in-class dry eye product portfolio."

    "In recent years the prevalence of dry eye disease has been rising while we've gained a better understanding of its multifactorial nature. In response, NovaBay offers a full portfolio of scientifically developed products for each step of the standard at-home dry eye treatment regimen," he added. "Our mission is for Avenova to become a one-stop destination for the 25 million Americans who suffer from dry eye."

    NovaBay's flagship product, Avenova Lid & Lash Solution, is designed to remove foreign material including microorganisms and debris from the skin around the eye as well as the eyelid. The Avenova product family also includes Avenova Lubricating Eye Drops for instant relief, Avenova Warm Eye Compress to soothe the eyes and the i-Chek by Avenova to monitor physical eyelid health. NovaBay also offers Avenova product bundles specifically designed to provide easy, affordable and effective solutions for individualized needs.

    About NovaBay Pharmaceuticals, Inc.

    NovaBay's leading product Avenova® Lid & Lash Solution is often recommended by eyecare professionals for blepharitis and dry eye disease. Manufactured in the U.S., Avenova spray is formulated with NovaBay's patented, proprietary, stable and pure form of hypochlorous acid. All Avenova products are available directly to consumers through online distribution channels such as Amazon.com and Avenova.com.

    Forward-Looking Statements

    This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, but not limited to, statements that are based upon management's current expectations, assumptions, estimates, projections and beliefs. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by the forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, risks and uncertainties relating to difficulties or delays in manufacturing, distributing, and selling the Company's products. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Other risks relating to the Company's business, including risks that could cause results to differ materially from those projected in the forward-looking statements in this press release, are detailed in the Company's latest Form 10-Q/K filings with the SEC, as may be amended from time to time, especially under the heading "Risk Factors." The forward-looking statements in this release speak only as of this date, and the Company disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.

    Socialize and Stay Informed on NovaBay's Progress

    Like us on Facebook

    Follow us on X

    Connect with NovaBay on LinkedIn

    Visit NovaBay's Website

    Avenova Purchasing Information

    For NovaBay Avenova purchasing information:

    Please call 800-890-0329 or email [email protected]

    Avenova.com

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240730296981/en/

    Get the next $NBY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NBY

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NBY
    SEC Filings

    View All

    NovaBay Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - NovaBay Pharmaceuticals, Inc. (0001389545) (Filer)

    2/11/26 9:48:38 PM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by NovaBay Pharmaceuticals Inc.

    DEF 14A - NovaBay Pharmaceuticals, Inc. (0001389545) (Filer)

    2/9/26 9:14:11 PM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NovaBay Pharmaceuticals Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Other Events

    8-K - NovaBay Pharmaceuticals, Inc. (0001389545) (Filer)

    1/30/26 5:09:15 PM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NBY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Poplar Point Capital Partners Lp bought $15,967 worth of shares (28,731 units at $0.56) (SEC Form 4)

    4 - NovaBay Pharmaceuticals, Inc. (0001389545) (Issuer)

    4/15/25 12:50:08 PM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Poplar Point Capital Partners Lp bought $74,519 worth of shares (123,365 units at $0.60) (SEC Form 4)

    4 - NovaBay Pharmaceuticals, Inc. (0001389545) (Issuer)

    4/15/25 12:46:27 PM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Poplar Point Capital Partners Lp bought $30,718 worth of shares (49,927 units at $0.62) (SEC Form 4)

    4 - NovaBay Pharmaceuticals, Inc. (0001389545) (Issuer)

    4/15/25 12:40:59 PM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NBY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Lazar David E. was granted 6,388,000 shares (SEC Form 4)

    4 - NovaBay Pharmaceuticals, Inc. (0001389545) (Issuer)

    1/29/26 7:30:12 PM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Framework Ventures Iv L.P. converted options into 56,806,080 shares (SEC Form 4)

    4 - NovaBay Pharmaceuticals, Inc. (0001389545) (Issuer)

    11/3/25 9:39:23 PM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner R01 Fund Lp converted options into 56,806,080 shares (SEC Form 4)

    4 - NovaBay Pharmaceuticals, Inc. (0001389545) (Issuer)

    11/3/25 9:38:56 PM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NBY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NovaBay Pharmaceuticals, Inc. Regains Compliance with NYSE American Continued Listing Standards

    EMERYVILLE, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE:NBY) ("NovaBay" or the "Company") announces that it has regained compliance with the NYSE American's continued listing standards. As previously disclosed, the NYSE American notified the Company on April 18, 2024 and May 28, 2024 that it was not in compliance with the continued listing standards of the NYSE American Company Guide. Specifically, the notifications indicated that the Company was not in compliance with Sections 1003(a)(i), 1003(a)(ii) and 1003(a)(iii) of the Company guide, requiring a listed company to have stockholders' equity of at least $6 million. Following the issuance and sale of p

    10/20/25 7:07:28 PM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NovaBay Pharmaceuticals Issues a Reminder of Important Information Regarding the Pending Special Dividend and Upcoming 2025 Annual Meeting

    EMERYVILLE, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) (the "Company") previously announced a one-time special cash dividend of $0.80 per share for the Company's common stock. The special cash dividend will be payable on September 29, 2025 to stockholders of record as of the close of business on September 15, 2025. Because the payment of the special dividend represents more than 25% of the price of the Company's common stock, NYSE American advised the Company that its common stock will trade with "due bills" representing an assignment of the right to receive the special dividend from the record date of September 15, 2025 through the close of tradi

    9/18/25 4:30:00 PM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NovaBay Pharmaceuticals Announces One-Time Special Cash Dividend of $0.80 Per Share

    EMERYVILLE, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) ("NovaBay" or the "Company") announces its Board of Directors and the Special Transaction Committee of the Board of Directors has declared a one-time special cash dividend of $0.80 per share of common stock. The special cash dividend will be payable on September 29, 2025 to stockholders of record as of the close of business on September 15, 2025. "This special dividend reflects our commitment to creating and returning value directly to our stockholders," said David Lazar, CEO of NovaBay. "I'm excited about the Company's future as we explore several interesting strategic alternatives." Because

    8/26/25 4:05:00 PM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NBY
    Financials

    Live finance-specific insights

    View All

    NovaBay Pharmaceuticals Announces One-Time Special Cash Dividend of $0.80 Per Share

    EMERYVILLE, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) ("NovaBay" or the "Company") announces its Board of Directors and the Special Transaction Committee of the Board of Directors has declared a one-time special cash dividend of $0.80 per share of common stock. The special cash dividend will be payable on September 29, 2025 to stockholders of record as of the close of business on September 15, 2025. "This special dividend reflects our commitment to creating and returning value directly to our stockholders," said David Lazar, CEO of NovaBay. "I'm excited about the Company's future as we explore several interesting strategic alternatives." Because

    8/26/25 4:05:00 PM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NovaBay Pharmaceuticals Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar

    EMERYVILLE, Calif., Aug. 19, 2025 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) ("NovaBay" or the "Company") announces it has entered into a $6 million securities purchase agreement with private investor David E. Lazar for the purchase of the Company's non-voting convertible preferred stock. NovaBay has received $3.85 million in the first of two closings under the agreement. Effective immediately, Mr. Lazar has been appointed NovaBay's Chief Executive Officer and a director of the Company. Former Chief Executive Officer Justin Hall has assumed the newly created position of Vice President of Business Development. At NovaBay's Special Meeting on April 16, 2025, stockholders

    8/19/25 5:25:32 PM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NovaBay Pharmaceuticals to Hold Second Quarter 2024 Conference Call on August 13, 2024

    NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) announces that it will report financial results for the three and six months ended June 30, 2024 after market close on Tuesday, August 13, 2024 and will hold an investment community conference call that day beginning at 4:30 p.m. Eastern time. Date/Time: Tuesday, August 13, 4:30 p.m. ET / 1:30 p.m. PT   Pre-Registration: Participants can pre-register for the conference call here:   Callers who pre-register will be emailed conference details and unique Registration ID to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time, including up to and

    8/1/24 6:50:00 AM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NBY
    Leadership Updates

    Live Leadership Updates

    View All

    NovaBay Pharmaceuticals Issues a Reminder of Important Information Regarding the Pending Special Dividend and Upcoming 2025 Annual Meeting

    EMERYVILLE, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) (the "Company") previously announced a one-time special cash dividend of $0.80 per share for the Company's common stock. The special cash dividend will be payable on September 29, 2025 to stockholders of record as of the close of business on September 15, 2025. Because the payment of the special dividend represents more than 25% of the price of the Company's common stock, NYSE American advised the Company that its common stock will trade with "due bills" representing an assignment of the right to receive the special dividend from the record date of September 15, 2025 through the close of tradi

    9/18/25 4:30:00 PM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Innovations in Disinfection Technology Aid the Return of Workers

    NEW YORK, Dec. 9, 2020 /PRNewswire/ -- The current pandemic has been devastating for the global economy and has caused severe backlogs in hospitals. Additionally, a spike in demand for Personal Protective Equipment (PPE) and new disinfecting technologies has also been seen. For example, when it comes for PPE, the global market was valued at USD 52.7 Billion in 2019 and is expected to reach USD 92.5 Billion by 2025 while growing at a CAGR of 8.7% during 2020-2025, according to VynZ Research. As for new technologies for disinfection, a recent example comes from LG Electronics, which announced on Wednesday the launch of a disinfection robot that will assist in containing the spread of the vi

    12/9/20 9:00:00 AM ET
    $NBY
    $CEMI
    $BSGM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Biotechnology: Electromedical & Electrotherapeutic Apparatus

    $NBY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by NovaBay Pharmaceuticals Inc.

    SC 13G/A - NovaBay Pharmaceuticals, Inc. (0001389545) (Subject)

    11/8/24 5:31:40 PM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by NovaBay Pharmaceuticals Inc. (Amendment)

    SC 13G/A - NovaBay Pharmaceuticals, Inc. (0001389545) (Subject)

    2/14/24 2:52:33 PM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by NovaBay Pharmaceuticals Inc. (Amendment)

    SC 13G/A - NovaBay Pharmaceuticals, Inc. (0001389545) (Subject)

    2/13/24 5:17:39 PM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care